ShanXi C&Y Pharmaceutical Group (300254) Fair Value & Analysis
Healthcare · CN · Market cap 2.4B CNY
Fair value as of: Jul 9, 2026
From 26 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥4.92 to ¥2.14 (−56.5%) since Jun 24, 2026. Share price +7.2% over the past month.
A solid business, but screening 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥2.67). The favourable scenario is already priced in.
- Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥5.00 – ¥14.68 · fair‑value band ¥1.60 – ¥2.67 · the ¥8.83 price screens above the ¥2.14 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
ShanXi C&Y Pharmaceutical Group (300254) currently trades at ¥8.83, while our model-based Fair Value estimate is ¥2.14, implying the stock looks roughly 75.8% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, ShanXi C&Y Pharmaceutical Group generated revenue of 863M CNY at a net margin of 2.1%. Revenue declined 4.4% year over year. It earns a return on equity of 8.7%. Net debt stands at 170M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥1.60 (bear case) to ¥2.67 (bull case); at ¥8.83, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -76%, 300254 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥3.49) versus Earnings-Based (¥0.4900). Highest evidence: Growth DCF (80).
Notify me when 300254 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products.
Full company description
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company's product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to ShanXi C&Y Pharmaceutical Group Co.,LTD. in September 2014. The company was founded in 2005 and is based in Datong, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ShanXi C&Y Pharmaceutical Group reported revenue of ¥871M in FY2025 versus ¥930M in FY2021, a compound −1.6%/yr. Reported net income was ¥24.9M in FY2025.
of which total revenue +3.1 pp · buybacks/dilution −2.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
300254 screens 76% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare ShanXi C&Y Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ShanXi C&Y Pharmaceutical Group (300254) overvalued or undervalued?
What is the fair value of 300254?
What is the quality score of 300254?
What is the revenue of ShanXi C&Y Pharmaceutical Group (300254)?
What is the net profit margin of 300254?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track ShanXi C&Y Pharmaceutical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.